DNA damage induced apoptosis suppressorGenealiases: C11orf82 · noxin
Q-omics provides the consensus-scored DDIAS profile across patient tissues and cancer cell-line models. DDIAS expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DDIAS is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, DDIAS RNA expression shows 24,704 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where DDIAS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDIAS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDIAS survival associations across molecular data types. DDIAS RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDIAS RNA expression–survival associations across cancer types. High DDIAS expression shows unfavorable associations in ACC, MESO, KIRP, KICH, LIHC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DDIAS RNA expression.
This table summarizes DDIAS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for DDIAS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDIAS shows higher tumor expression in HNSC, BLCA, COAD, KIRP, LIHC and STAD. The HNSC box plot shows higher DDIAS RNA expression in tumor versus normal tissue (log2 FC = +1.447, t-test p < 0.001).
This table shows molecular features associated with DDIAS in patient tissues and cancer cell lines. In patient samples, DDIAS shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DDIAS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
